> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vertex Cystic Fibrosis NDA Used Priority Voucher
- URL: https://www.fdaweb.com/vertex-cystic-fibrosis-nda-used-priority-voucher/
- Published: 2025-01-09T12:00:00.000Z
- Updated: 2026-09-14T14:50:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158456

*Federal Register* notice: FDA announces that a priority review voucher was used with the agency’s 12/20/2024 approval of Vertex Pharmaceuticals’ Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator modulator for treating cystic fibrosis in people six years and older who have at least one F508del mutation. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2025-01-10/pdf/2025-00341.pdf?ref=fdaweb.com).